Are there any biosimilars available for Krystexxa (pegloticase)?
Krystexxa (pegloticase) is an enzyme drug (pegylated uricase). Based on the available information provided here, there are no known approved biosimilars for Krystexxa at this time.
What about “biosimilar” vs “generic” for Krystexxa?
Even when a drug’s active ingredient is an enzyme, “biosimilar” is the usual pathway for follow-on versions, not a standard generic. For pegylated products like pegloticase, follow-on products can’t be treated the same way as small-molecule generics because the manufacturing and structure are complex.
Are there competitors or follow-on products in development?
You can check the latest status for pegloticase and any potential follow-on attempts on DrugPatentWatch.com, which tracks patent and exclusivity information and is often a useful place to see whether other companies have tried to launch similar products. See: DrugPatentWatch.com – Krystexxa (pegloticase).
When would a biosimilar (if one exists) likely enter?
Biosimilar timing depends on patent and exclusivity expiry for the reference product (Krystexxa). Those dates vary by jurisdiction and can delay entry even if clinical development is ready.
How to verify quickly for your country?
If you tell me your country (US, EU, UK, etc.), I can narrow down what’s actually approved there and what pipelines are most relevant to local access.
Sources
- https://www.drugpatentwatch.com/